Biocompatible targeted drug release management platform

Through the biocompatible targeted drug release management platform, the recurrent neural network and genetic algorithm are used to adjust drug release in real time, and combined with biomarker monitoring and clinical data, the drug release strategy is optimized, which solves the problem of drug release in traditional technology that does not adapt to the physiological status of patients. The problem of this achieves efficient and precise targeted treatment.

CN119068971AInactive Publication Date: 2024-12-03ZHUHAI SHUANGZHE BIOTECHNOLOGY CO LTD
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202410940327.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-15
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Traditional targeted drug release technology lacks adaptability to patients' unique physiological state, resulting in drug release not meeting actual needs, increasing the risk of adverse reactions, wasting treatment resources, and performing poorly in rapidly changing pathological states, increasing treatment uncertainty .

Method used

Adopt biocompatible targeted drug release management platform, including drug release timing adjustment module, drug release effect prediction module, targeted drug trigger detection module, drug release strategy optimization module, drug carrier molecular design module and drug release monitoring module, using Recurrent neural networks and genetic algorithms adjust drug dose and release time in real time, combine biomarker monitoring and clinical data, optimize drug release strategies and vector design, and improve targeted treatment accuracy and efficiency.

Benefits of technology

By accurately adjusting drug release, ensure that the drug works at the optimal time and dose, significantly improve the targeting accuracy and treatment efficiency of the drug, reduce adverse reactions, and improve the patient's treatment experience and safety.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119068971A_ABST
    Figure CN119068971A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of targeted drug release, in particular to a biocompatible targeted drug release management platform, which comprises a drug release opportunity adjusting module for monitoring physiological data of a patient based on the heart rate, the blood pressure and the respiratory rate of the patient, predicting the short-term physiological change trend of the patient by adopting a recurrent neural network, and adjusting the drug release opportunity according to the short-term physiological change trend. And the drug dosage and the release time are adjusted in real time to obtain adjusted drug release parameters. In the invention, through the recurrent neural network and the genetic algorithm, the future treatment response is predicted, the drug release is accurately adjusted, the drug is ensured to play a role at the optimal time and dosage, the adjusted drug release parameter and clinical data are utilized to evaluate and predict the treatment effect, and accurate data support is provided for disease treatment. The carrier response is monitored and adjusted in real time through the biomarker, so that the targeting precision and treatment efficiency of the medicine are remarkably improved, the medicine release strategy is accurately adjusted, the adverse reaction of a patient is reduced, and the treatment experience and safety of the patient are improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of targeted drug release, and in particular to a biocompatible targeted drug release management platform. Background Art

[0002] The field of targeted drug release technology focuses on developing technologies that can precisely control the release of drugs in the body. Through specific drug carriers or systems, drugs can be released in targeted locations or tissues that require treatment, thereby maximizing the therapeutic effect and reducing the occurrence of adverse reactions.

[0003] The biocompatible targeted drug release management platform is designed to manage and control the drug release process in the body, ensuring that the drug is released at the right time and place to achieve the best therapeutic effect. It usually combines advanced drug carrier technology and controlled release mechanism, as well as biocompatible materials suitable for specific tissue or disease needs.

[0004] Traditional technologies rely on preset release patterns and lack adaptability to the patient's unique physiological state, resulting in drug release at a time and place that does not match the patient's actual needs. Drugs may be released when the patient is in poor physical condition, increasing the risk of adverse reactions, and excessive drug release when not needed, resulting in a waste of treatment resources. They do not take into account the physiological differences between individuals, resulting in insufficient or excessive drug efficacy, affecting the treatment effect, and perform poorly when responding to rapidly changing pathological conditions, increasing uncertainty in the treatment process and the treatment burden on patients. Summary of the invention

[0005] The purpose of the present invention is to solve the shortcomings of the prior art and to propose a biocompatible targeted drug release management platform.

[0006] In order to achieve the above-mentioned purpose, the present invention adopts the following technical scheme: a biocompatible targeted drug release management platform, comprising:

[0007] Drug release timing adjustment module: Based on the patient's heart rate, blood pressure and respiratory rate, the module monitors the patient's physiological data, and uses a recurrent neural network to predict the patient's short-term physiological change trend, and adjusts the drug dosage and release time in real time to obtain the adjusted drug release parameters;

[0008] Drug release effect prediction module: using the adjusted drug release parameters, combined with large-scale clinical data, to analyze the treatment effect, evaluate the effects of different doses and release strategies on specific symptoms, accurately simulate and predict future treatment responses, and generate drug treatment effect prediction values;

[0009] Targeted drug trigger detection module: through the predicted value of drug treatment effect, monitor biomarkers such as specific proteins or cell markers, directly trigger the intelligent carrier to release drugs, use genetic algorithms to adjust the carrier response in real time, improve the accuracy of targeted treatment, and generate targeted drug trigger indicators;

[0010] Drug release strategy optimization module: based on the targeted drug triggering index, adjust the release strategy, refine the time and dosage of drug release, adapt to the patient's health status in real time, optimize the balance between efficacy and side effects, and obtain the optimized drug release strategy;

[0011] Drug carrier molecular design module: Based on the optimized drug release strategy, optimize the carrier molecular structure, enhance the recognition and binding ability of the carrier with pathological markers, improve the targeting and efficiency of the carrier design, and create carrier design optimization results;

[0012] Drug release monitoring module: Based on the carrier design optimization results, monitor the operating efficiency and accuracy of the drug release system, refine the system adjustment parameters, improve the overall treatment effect, and generate drug release monitoring data.

[0013] As a further solution of the present invention, the drug release timing adjustment module includes a physiological data monitoring submodule, a physiological trend prediction submodule and a drug adjustment control submodule, wherein:

[0014] The physiological data monitoring submodule continuously collects heart rate, blood pressure and respiratory rate data, cleans and integrates the data, and generates a comprehensive physiological data report;

[0015] The physiological trend prediction submodule uses a recurrent neural network based on the comprehensive report of physiological data to predict the changes in the patient's physiological data in the short term and build a physiological trend prediction model;

[0016] The recurrent neural network, according to the formula:

[0017] h t =f(W·[h t-1 ,x t ,e t ,c t ]+b+β)

[0018] Where: h t is the hidden state at time t, h t-1 is the hidden state at time t-1, x t is the input feature vector at time t, e t is the environmental factor code at time t, c t is the clinical parameter encoding at time t, W is the network weight parameter, b is the bias parameter, β is the additional bias, and f is the nonlinear activation function;

[0019] The drug adjustment control submodule adjusts the output parameter settings of the drug pump based on the physiological trend prediction model, updates the drug dosage and release time in real time, and obtains the optimized drug release parameters.

[0020] As a further solution of the present invention, the drug release effect prediction module includes a clinical data analysis submodule, a treatment effect evaluation submodule and a simulation prediction generation submodule, wherein:

[0021] The clinical data analysis submodule screens the data sets related to the optimized drug release parameters, counts and analyzes the data characteristics and distribution, and generates data analysis results;

[0022] The treatment effect evaluation submodule compares and analyzes the differences in the effects of treatment plans on symptoms based on the data analysis results, and evaluates the treatment effects of each plan to obtain a treatment effect evaluation report;

[0023] The simulation prediction generation submodule simulates different treatment strategies based on the treatment effect evaluation report, draws response curves, and establishes a comprehensive prediction model.

[0024] As a further solution of the present invention, the targeted drug trigger detection module includes a biomarker monitoring submodule, a smart carrier response submodule and a drug release trigger submodule, wherein:

[0025] The biomarker monitoring submodule tracks the concentration changes of specific proteins and cell markers based on the biomarker monitoring needs, and records the activity fluctuations of biomarkers to generate biomarker activity records;

[0026] The intelligent carrier response submodule uses a genetic algorithm to adjust the drug release mechanism in the carrier according to the biomarker activity record, keeps the drug release state synchronized with the biomarker activity state, and updates the drug release parameters in real time to obtain a drug release regulation strategy;

[0027] The genetic algorithm, according to the formula:

[0028]

[0029] Where: x is the drug release rate, y is the concentration of the biomarker, z is the distribution coefficient of the drug in the body, t is the time variable, a is the maximum potential value of the drug release effect, b is the sensitivity to the regulation of the drug release rate, d is the weight coefficient of the biomarker concentration, e and c are constants, and f(z,t) is a composite function;

[0030] The drug release triggering submodule accurately controls drug release according to the drug release regulation strategy, adjusts the release time and dosage to match the real-time biofeedback, and records the precise time and dosage of drug release, ultimately obtaining an optimized drug release strategy.

[0031] As a further solution of the present invention, the drug release strategy optimization module includes a release strategy refinement submodule, a health status adaptation submodule and a side effect balance submodule, wherein:

[0032] The release strategy refinement submodule refines the specific time and dosage arrangement of drug release based on the optimized drug release strategy, records the drug release requirements at different time points, and adjusts the dosage adjustment plan to generate a refined release schedule;

[0033] The health status adaptation submodule adjusts the drug release plan based on the detailed release schedule and the patient's real-time health status data, and synchronously updates the drug dosage and time to adapt to health changes, thereby obtaining a health adaptation plan;

[0034] The side effect balance submodule balances the efficacy and side effects in the drug release strategy according to the health adaptation plan, reduces adverse effects by adjusting release parameters, continuously monitors efficacy and side effect data, and generates efficacy and side effect regulation records.

[0035] As a further solution of the present invention, the drug carrier molecule design module includes a carrier structure optimization submodule, a marker recognition enhancement submodule and a targeting enhancement submodule, wherein:

[0036] The carrier structure optimization submodule, based on the optimized drug release strategy, adjusts the physical and chemical properties of the carrier molecules in detail, reconfigures the arrangement and linking of the molecular chains, strengthens the stability of the structure, and records the changes in the molecular structure to generate a structural optimization plan;

[0037] The marker recognition enhancer module adjusts the functional groups on the carrier molecule according to the structural optimization scheme to improve its affinity with the pathological marker, reconfigures the structure of the recognition site to ensure accurate matching with the pathological marker, and performs efficiency testing to obtain a record of improved recognition ability;

[0038] The targeting enhancement submodule adjusts the spatial structure of the carrier molecule based on the recognition ability enhancement record to ensure its targeting to specific pathological markers, and adjusts the binding efficiency between the drug molecule and the carrier, records the accuracy and speed of each adjustment, and obtains the targeting efficiency result.

[0039] As a further solution of the present invention, the drug release monitoring module includes a release efficiency monitoring submodule, a system adjustment parameter refinement submodule and a therapeutic effect improvement monitoring submodule, wherein:

[0040] The release efficiency monitoring submodule is based on the targeting efficiency results, by recording the release rate and concentration of the drug under different conditions, comparing the release efficiency at different time points and environmental conditions, analyzing the uniformity and speed of drug release, and continuously monitoring to generate release efficiency data;

[0041] The system adjustment parameter refinement submodule accurately adjusts the parameters of the drug release system based on the release efficiency data, optimizes the parameter settings according to the real-time data, adjusts the reaction sensitivity and time window of the release mechanism, and records the specific operations and results of each adjustment to obtain parameter adjustment records;

[0042] The efficacy improvement monitoring submodule adjusts the records according to the parameters, makes quantitative adjustments to the drug dosage and release frequency, makes feedback adjustments based on the treatment effect, and records and adjusts the key data and results in the process according to the drug response and pathological changes to obtain the efficacy optimization results.

[0043] Compared with the prior art, the advantages and positive effects of the present invention are:

[0044] In the present invention, recurrent neural networks and genetic algorithms are used to predict future treatment responses and accurately adjust drug release to ensure that the drug works at the optimal time and dosage. The adjusted drug release parameters and clinical data are used to evaluate and predict the treatment effect, providing accurate data support for disease treatment. Through biomarker monitoring, the carrier response is adjusted in real time, which significantly improves the drug's targeting accuracy and treatment efficiency, accurately adjusts the drug release strategy, reduces patients' adverse reactions, and improves patients' treatment experience and safety. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 is a system flow chart of the present invention;

[0046] Figure 2 It is a schematic diagram of the system framework of the present invention. DETAILED DESCRIPTION

[0047] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0048] Embodiment 1

[0049] See also Figure 1 The present invention provides a technical solution: a biocompatible targeted drug release management platform, comprising:

[0050] Drug release timing adjustment module: Based on the patient's heart rate, blood pressure and respiratory rate, the module monitors the patient's physiological data, and uses a recurrent neural network to predict the patient's short-term physiological change trend, and adjusts the drug dosage and release time in real time to obtain the adjusted drug release parameters;

[0051] Drug release effect prediction module: uses adjusted drug release parameters and combines large-scale clinical data to analyze treatment effects, evaluate the effects of different doses and release strategies on specific symptoms, accurately simulate and predict future treatment responses, and generate drug treatment effect prediction values;

[0052] Targeted drug trigger detection module: through the prediction value of drug treatment effect, monitor biomarkers such as specific proteins or cell markers, directly trigger the intelligent carrier to release drugs, use genetic algorithms to adjust the carrier response in real time, improve the accuracy of targeted treatment, and generate targeted drug trigger indicators;

[0053] Drug release strategy optimization module: Based on the targeted drug triggering index, adjust the release strategy, refine the time and dosage of drug release, adapt to the patient's health status in real time, optimize the balance between efficacy and side effects, and obtain the optimized drug release strategy;

[0054] Drug carrier molecular design module: Based on the optimized drug release strategy, optimize the carrier molecular structure, enhance the recognition and binding ability of the carrier with pathological markers, improve the targeting and efficiency of the carrier design, and create carrier design optimization results;

[0055] Drug release monitoring module: Based on the carrier design optimization results, monitor the operating efficiency and accuracy of the drug release system, refine the system adjustment parameters, improve the overall treatment effect, and generate drug release monitoring data.

[0056] See also Figure 2 The drug release timing adjustment module includes a physiological data monitoring submodule, a physiological trend prediction submodule and a drug adjustment control submodule, wherein:

[0057] The physiological data monitoring submodule continuously collects heart rate, blood pressure and respiratory rate data, cleans and integrates the data, and generates a comprehensive physiological data report;

[0058] The physiological trend prediction submodule uses a recurrent neural network based on the comprehensive report of physiological data to predict the changes in the patient's physiological data in the short term and build a physiological trend prediction model;

[0059] Recurrent neural network, according to the formula:

[0060] h t =f(W·[h t-1 ,x t ,e t ,c t]+b+β)

[0061] Where: h t is the hidden state at time t, h t-1 is the hidden state at time t-1, x t is the input feature vector at time t, e t is the environmental factor code at time t, c t is the clinical parameter encoding at time t, W is the network weight parameter, b is the bias parameter, β is the additional bias, and f is the nonlinear activation function;

[0062] Execution process: First, the network integrates the hidden state h t-1 And the input feature x t , adding environmental factors t and clinical parameters c t To provide a more comprehensive view of the data, the same weight matrix W is integrated to increase the model's responsiveness to external variables. The additional bias β is determined through a simple training process, including adjustment using the mean square error minimization on the validation dataset, so that the model more accurately reflects the patient's physiological changes. The integrated result is processed by the activation function f to output the final hidden state h t , thereby generating a more accurate physiological trend prediction model.

[0063] The drug adjustment control submodule adjusts the output parameter settings of the drug pump based on the physiological trend prediction model, updates the drug dosage and release time in real time, and obtains the optimized drug release parameters;

[0064] The physiological data monitoring submodule continuously collects heart rate, blood pressure and respiratory rate data, using statistical methods, specifically the moving average method, with parameters including a time window set to 5 minutes, averaging the data points every minute to reduce the impact of instantaneous fluctuations, filtering the data for noise, and integrating the data to generate a comprehensive report on physiological data;

[0065] The physiological trend prediction submodule is based on the comprehensive report of physiological data and adopts a recurrent neural network, specifically a long short-term memory network. The parameters include the number of input layer nodes corresponding to the data points per minute, the number of hidden layer nodes is set to 100, the number of training rounds is set to 50 rounds, and the learning rate is set to 0.01. It predicts the changes in the patient's physiological data in the short term, builds a physiological trend prediction model, and generates physiological trend prediction results;

[0066] The drug adjustment control submodule is based on the physiological trend prediction model and adopts a control algorithm, specifically a proportional-integral-differential controller PID. The parameters include the proportional coefficient set to 0.1, the integral coefficient set to 0.01, and the differential coefficient set to 0.05. The target setting value corresponds to the stable state target value in the physiological trend prediction result. The output parameter setting of the drug pump is adjusted, the drug dosage and release time are updated in real time, and the optimized drug release parameters are generated.

[0067] See also Figure 2 The drug release effect prediction module includes a clinical data analysis submodule, a therapeutic effect evaluation submodule and a simulation prediction generation submodule, among which:

[0068] The clinical data analysis submodule screens and optimizes data sets related to drug release parameters, counts and analyzes data characteristics and distribution, and generates data analysis results;

[0069] The treatment effect evaluation submodule compares and analyzes the differences in the effects of treatment plans on symptoms based on the data analysis results, and evaluates the treatment effects of each plan to obtain a treatment effect evaluation report;

[0070] The simulation prediction generation submodule simulates different treatment strategies based on the treatment effect evaluation report, draws response curves, and establishes a comprehensive prediction model;

[0071] In the clinical data analysis submodule, we screened and optimized the data sets related to drug release parameters, used the data analysis library Pandas, used the DataFrame structure to store data, set the filtering conditions to the data rows containing specific drug parameter identifiers, performed data statistical operations, including calculating the mean and standard deviation, analyzed the data characteristics and distribution, and generated data analysis results;

[0072] In the treatment effect evaluation submodule, based on the data analysis results, a statistical test method is used, specifically a t-test, which is implemented using the SciPy library. The parameter settings include the degree of freedom being the number of samples minus one, the significance level being set to 0.05, and the difference in the effects of different treatment plans on the symptoms is compared and analyzed. The plans are compared and a treatment effect evaluation report is generated.

[0073] In the simulation prediction generation submodule, based on the treatment effect evaluation report, the Monte Carlo simulation method was used to generate random numbers using the NumPy library. The parameters included setting the number of simulations to 10,000 times and using normal distribution to simulate patient responses), simulating different treatment strategies, drawing response curves, using polynomial regression to fit the curves, building a comprehensive prediction model, and generating simulation prediction results.

[0074] See also Figure 2 The targeted drug trigger detection module includes a biomarker monitoring submodule, an intelligent carrier response submodule and a drug release trigger submodule, wherein:

[0075] The biomarker monitoring submodule tracks the concentration changes of specific proteins and cell markers based on the biomarker monitoring needs, and records the activity fluctuations of biomarkers to generate biomarker activity records;

[0076] The intelligent carrier response submodule uses genetic algorithms to adjust the drug release mechanism in the carrier according to the biomarker activity records, keeps the drug release status synchronized with the biomarker activity status, and updates the drug release parameters in real time to obtain the drug release regulation strategy;

[0077] Genetic algorithm, according to the formula:

[0078]

[0079] Where: x is the drug release rate, y is the concentration of the biomarker, z is the distribution coefficient of the drug in the body, t is the time variable, a is the maximum potential value of the drug release effect, b is the sensitivity to the regulation of the drug release rate, d is the weight coefficient of the biomarker concentration, e and c are constants, and f(z,t) is a composite function;

[0080] Execution process: First, according to the current concentration y of the biomarker and the distribution coefficient z of the drug, combined with the time variable t, the drug release rate x is calculated by adjusting the coefficients a, b, c, d, and e, and the function Calculate the fitness of the current drug release state, combine the logarithmic adjustment of the biomarker concentration d·log(y+e), consider the influence of drug distribution and time variables through the function f(z,t), integrate all parameters, and adjust the drug release strategy in real time. The determination of weight coefficients a, b, c, d, and e needs to be optimized through experimental data, and iteratively find the optimal parameter combination to ensure that drug release and biomarker activity are synchronized to the greatest extent.

[0081] The drug release trigger submodule accurately controls drug release according to the drug release regulation strategy, adjusts the release time and dosage to match the real-time biofeedback, and records the precise time and dosage of drug release, ultimately obtaining an optimized drug release strategy;

[0082] In the biomarker monitoring submodule, based on the biomarker monitoring needs, spectral analysis technology is used to measure the concentration of specific proteins and cell markers using a spectrometer, the spectral scanning range is set to 200-800nm, the acquisition frequency is set to once every 10 seconds, data acquisition operations are performed, biomarker activity fluctuations are recorded, and biomarker activity records are generated;

[0083] In the smart carrier response submodule, a genetic algorithm is used to adjust the drug release mechanism in the carrier according to the biomarker activity record. Specifically, the algorithm population size is set to 100, the crossover rate is set to 0.7, and the mutation rate is set to 0.1. The fitness evaluation and selection of the drug release state are performed to maintain the synchronization of the drug release state with the activity state of the biomarker, and the drug release parameters are updated in real time, and the drug release regulation strategy is generated;

[0084] In the drug release triggering submodule, according to the drug release regulation strategy, a time control algorithm is adopted, specifically time series analysis, and the trigger threshold is set to when the drug concentration change rate exceeds 10%. Dynamic adjustment of drug release time and dosage is performed to adjust the release time and dosage to match the real-time biofeedback, and the precise time and dosage of drug release are recorded, and an optimized drug release strategy is generated.

[0085] See also Figure 2 The drug release strategy optimization module includes a release strategy refinement submodule, a health status adaptation submodule, and a side effect balance submodule, among which:

[0086] The release strategy refinement submodule refines the specific time and dosage schedule of drug release based on the optimized drug release strategy, records the drug release requirements at different time points, and adjusts the dosage adjustment plan to generate a refined release schedule;

[0087] The health status adaptation submodule adjusts the drug release plan based on the detailed release schedule and the patient's real-time health status data, and synchronously updates the drug dosage and time to adapt to health changes to obtain a health adaptation plan;

[0088] The side effect balance submodule balances the efficacy and side effects in the drug release strategy according to the health adaptation plan, reduces adverse effects by adjusting the release parameters, continuously monitors the efficacy and side effect data, and generates efficacy and side effect regulation records;

[0089] In the release strategy refinement submodule, based on the established drug release strategy, the time series analysis method is used, and the Python Pandas library is used to process the time data, program the specific time and dosage schedule of drug release, record the drug release requirements at each time point, iteratively optimize the dosage adjustment scheme, and generate a refined release schedule;

[0090] In the health status adaptation submodule, based on the refined release schedule, the machine learning supervised learning method is adopted, and the scikit-learn library is used to implement regression analysis. The patient's real-time health status data is analyzed, and the drug release plan is dynamically adjusted according to the analysis results. The drug dosage and time are synchronously updated to adapt to health changes, and a health adaptation plan is generated;

[0091] In the side effect balance submodule, based on the health adaptation scheme, the decision tree algorithm is adopted and implemented using Python's DecisionTreeRegressor to model the relationship between efficacy and side effects, reduce adverse effects by adjusting release parameters, continuously monitor efficacy and side effect data, and generate efficacy and side effect regulation records.

[0092] See also Figure 2 The drug carrier molecular design module includes a carrier structure optimization submodule, a marker recognition enhancement submodule, and a targeting enhancement submodule, among which:

[0093] The carrier structure optimization submodule is based on the optimized drug release strategy. It adjusts the physical and chemical properties of the carrier molecules in detail, reconfigures the arrangement and connection of its molecular chains, strengthens the stability of the structure, and records the changes in the molecular structure to generate a structural optimization plan.

[0094] The marker recognition enhancer module adjusts the functional groups on the carrier molecule according to the structural optimization plan to improve its affinity with the pathological marker, reconfigures the structure of the recognition site to ensure accurate matching with the pathological marker, and conducts efficiency testing to obtain a record of improved recognition ability;

[0095] The targeting enhancement submodule adjusts the spatial structure of the carrier molecule based on the recognition ability enhancement record to ensure its targeting to specific pathological markers, and adjusts the binding efficiency between the drug molecule and the carrier at the same time, records the accuracy and speed of each adjustment, and obtains the targeting efficiency result;

[0096] In the carrier structure optimization submodule, molecular dynamics simulation method is used to fine-tune the physical and chemical properties of the carrier molecules using GROMACS software, set the simulation environment parameters, including temperature set to 298K and pressure set to 1atm, calculate the intermolecular interaction, reconfigure the arrangement and linking of the molecular chains by setting the simulation running time to 100ns, record the change process of the molecular structure, and generate a structural optimization plan.

[0097] In the marker recognition enhancer module, based on the structural optimization scheme, molecular docking technology was used, and the AutoDock tool was used to adjust the functional groups on the carrier molecule, set the algorithm parameters, including the population size set to 150 and the number of iterations set to 25,000, to improve its affinity with the pathological marker, reconfigure the structure of the recognition site, perform efficiency testing, and obtain the recognition ability improvement record.

[0098] In the targeting enhancement submodule, based on the recognition ability improvement records, the spatial conformation analysis method is adopted, and the Chem3D software is used to set the spatial adjustment parameters, adjust the spatial structure of the carrier molecule, ensure its targeting to specific pathological markers, and adjust the binding efficiency between the drug molecule and the carrier at the same time. The accuracy and speed of each adjustment are recorded to obtain the targeting efficiency results.

[0099] See also Figure 2 The drug release monitoring module includes a release efficiency monitoring submodule, a system adjustment parameter refinement submodule and an efficacy improvement monitoring submodule, among which:

[0100] The release efficiency monitoring submodule is based on the targeted efficiency results. It records the release rate and concentration of the drug under different conditions, compares the release efficiency at different time points and environmental conditions, analyzes the uniformity and speed of drug release, and performs continuous monitoring to generate release efficiency data.

[0101] The system adjustment parameter refinement submodule accurately adjusts the parameters of the drug release system based on the release efficiency data, optimizes the parameter settings according to real-time data, adjusts the reaction sensitivity and time window of the release mechanism, and records the specific operations and results of each adjustment to obtain parameter adjustment records;

[0102] The efficacy improvement monitoring submodule adjusts the drug dosage and release frequency quantitatively based on the parameter adjustment records, makes feedback adjustments based on the treatment effect, and records and adjusts the key data and results in the process according to the drug response and pathological changes to obtain the efficacy optimization results;

[0103] In the release efficiency monitoring submodule, based on the targeted efficiency results, the drug dynamic monitoring technology is used, and the time series analysis method is used to operate. The monitoring parameters are set, including the sample sampling frequency is set to once an hour, and the Python Pandas library is used for time indexing and data screening. The release rate and concentration of the drug under different conditions are recorded, and the release efficiency at different time points and environmental conditions is compared. The uniformity and speed of drug release are analyzed, and continuous monitoring is performed to generate release efficiency data.

[0104] In the system adjustment parameter refinement submodule, based on the release efficiency data, parameter optimization technology is used, and the grid search method in machine learning is used to set the search parameters, including the learning rate from 0.01 to 0.1. The Scikit-learn library is used to adjust the model parameters, and the parameters of the drug release system are accurately adjusted. The parameter settings are optimized according to the real-time data, the reaction sensitivity and time window of the release mechanism are adjusted, and the specific operations and results of each adjustment are recorded to obtain the parameter adjustment records.

[0105] In the efficacy improvement monitoring submodule, based on the parameter adjustment records, a dosage adjustment algorithm is adopted, and MATLAB is used for mathematical modeling operations. The algorithm parameters are set, including the drug dosage adjustment range from 1 mg to 10 mg, quantitative adjustment of drug dosage and release frequency, feedback adjustment based on the treatment effect, and key data and results in the process are recorded and adjusted according to drug reactions and pathological changes to obtain efficacy optimization results.

[0106] The above are only preferred embodiments of the present invention and are not intended to limit the present invention in other forms. Any technician familiar with the profession may use the technical contents disclosed above to change or modify them into equivalent embodiments with equivalent changes and apply them to other fields. However, any simple modification, equivalent change and modification made to the above embodiments based on the technical essence of the present invention without departing from the technical solution of the present invention still falls within the protection scope of the technical solution of the present invention.

Claims

1. A biocompatible targeted drug release management platform, It is characterized in that include: Drug release timing adjustment module: Based on the patient's heart rate, blood pressure and respiratory rate, the module monitors the patient's physiological data, and uses a recurrent neural network to predict the patient's short-term physiological change trend, and adjusts the drug dosage and release time in real time to obtain the adjusted drug release parameters; Drug release effect prediction module: using the adjusted drug release parameters, combined with large-scale clinical data, to analyze the treatment effect, evaluate the effects of different doses and release strategies on specific symptoms, accurately simulate and predict future treatment responses, and generate drug treatment effect prediction values; Targeted drug trigger detection module: through the predicted value of drug treatment effect, monitor biomarkers such as specific proteins or cell markers, directly trigger the intelligent carrier to release drugs, use genetic algorithms to adjust the carrier response in real time, improve the accuracy of targeted treatment, and generate targeted drug trigger indicators; Drug release strategy optimization module: based on the targeted drug triggering index, adjust the release strategy, refine the time and dosage of drug release, adapt to the patient's health status in real time, optimize the balance between efficacy and side effects, and obtain the optimized drug release strategy; Drug carrier molecular design module: Based on the optimized drug release strategy, optimize the carrier molecular structure, enhance the recognition and binding ability of the carrier with pathological markers, improve the targeting and efficiency of the carrier design, and create carrier design optimization results; Drug release monitoring module: Based on the carrier design optimization results, monitor the operating efficiency and accuracy of the drug release system, refine the system adjustment parameters, improve the overall treatment effect, and generate drug release monitoring data.

2. The biocompatible targeted drug release management platform according to claim 1, Features: The drug release timing adjustment module includes a physiological data monitoring submodule, a physiological trend prediction submodule and a drug adjustment control submodule, wherein: The physiological data monitoring submodule continuously collects heart rate, blood pressure and respiratory rate data, cleans and integrates the data, and generates a comprehensive physiological data report; The physiological trend prediction submodule uses a recurrent neural network based on the physiological data comprehensive report to predict the changes in the patient's physiological data in the short term and build a physiological trend prediction model; The recurrent neural network, according to the formula: h t =f(W·[h t-1 ,x t ,e t ,c t ]+b+β) Where: h t is the hidden state at time t, h t-1 is the hidden state at time t-1, x t is the input feature vector at time t, e t is the environmental factor code at time t, c t is the clinical parameter encoding at time t, W is the network weight parameter, b is the bias parameter, β is the additional bias, and f is the nonlinear activation function; The drug adjustment control submodule adjusts the output parameter settings of the drug pump based on the physiological trend prediction model, updates the drug dosage and release time in real time, and obtains optimized drug release parameters.

3. The biocompatible targeted drug release management platform according to claim 1, Features: The drug release effect prediction module includes a clinical data analysis submodule, a treatment effect evaluation submodule and a simulation prediction generation submodule, wherein: The clinical data analysis submodule screens the data sets related to the optimized drug release parameters, counts and analyzes the data characteristics and distribution, and generates data analysis results; The treatment effect evaluation submodule compares and analyzes the differences in the effects of treatment plans on symptoms based on the data analysis results, and evaluates the treatment effects of each plan to obtain a treatment effect evaluation report; The simulation prediction generation submodule simulates different treatment strategies based on the treatment effect evaluation report, draws response curves, and establishes a comprehensive prediction model.

4. The biocompatible targeted drug release management platform according to claim 1, Features: The targeted drug trigger detection module includes a biomarker monitoring submodule, an intelligent carrier response submodule and a drug release trigger submodule, wherein: The biomarker monitoring submodule tracks the concentration changes of specific proteins and cell markers based on the biomarker monitoring needs, and records the activity fluctuations of biomarkers to generate biomarker activity records; The intelligent carrier response submodule uses a genetic algorithm to adjust the drug release mechanism in the carrier according to the biomarker activity record, keeps the drug release state synchronized with the biomarker activity state, and updates the drug release parameters in real time to obtain a drug release regulation strategy; The genetic algorithm, according to the formula: Where: x is the drug release rate, i is the concentration of the biomarker, z is the distribution coefficient of the drug in the body, t is the time variable, a is the maximum potential value of the drug release effect, b is the sensitivity to the regulation of the drug release rate, d is the weight coefficient of the biomarker concentration, i and c are constants, and f(z,t) is a composite function; The drug release triggering submodule accurately controls drug release according to the drug release regulation strategy, adjusts the release time and dosage to match the real-time biofeedback, and records the precise time and dosage of drug release, ultimately obtaining an optimized drug release strategy.

5. The biocompatible targeted drug release management platform according to claim 1, Features: The drug release strategy optimization module includes a release strategy refinement submodule, a health status adaptation submodule and a side effect balance submodule, wherein: The release strategy refinement submodule refines the specific time and dosage arrangement of drug release based on the optimized drug release strategy, records the drug release requirements at different time points, and adjusts the dosage adjustment plan to generate a refined release schedule; The health status adaptation submodule adjusts the drug release plan based on the detailed release schedule and the patient's real-time health status data, and synchronously updates the drug dosage and time to adapt to health changes, thereby obtaining a health adaptation plan; The side effect balance submodule balances the efficacy and side effects in the drug release strategy according to the health adaptation plan, reduces adverse effects by adjusting release parameters, continuously monitors efficacy and side effect data, and generates efficacy and side effect regulation records.

6. The biocompatible targeted drug release management platform according to claim 1, Features: The drug carrier molecular design module includes a carrier structure optimization submodule, a marker recognition enhancement submodule and a targeting enhancement submodule, wherein: The carrier structure optimization submodule, based on the optimized drug release strategy, adjusts the physical and chemical properties of the carrier molecules in detail, reconfigures the arrangement and linking of the molecular chains, strengthens the stability of the structure, and records the changes in the molecular structure to generate a structural optimization plan; The marker recognition enhancer module adjusts the functional groups on the carrier molecule according to the structural optimization scheme to improve its affinity with the pathological marker, reconfigures the structure of the recognition site to ensure accurate matching with the pathological marker, and performs efficiency testing to obtain a record of improved recognition ability; The targeting enhancement submodule adjusts the spatial structure of the carrier molecule based on the recognition ability enhancement record to ensure its targeting to specific pathological markers, and adjusts the binding efficiency between the drug molecule and the carrier, records the accuracy and speed of each adjustment, and obtains the targeting efficiency result.

7. The biocompatible targeted drug release management platform according to claim 1, Features: The drug release monitoring module includes a release efficiency monitoring submodule, a system adjustment parameter refinement submodule and a therapeutic effect improvement monitoring submodule, wherein: The release efficiency monitoring submodule is based on the targeting efficiency results, by recording the release rate and concentration of the drug under different conditions, comparing the release efficiency at different time points and environmental conditions, analyzing the uniformity and speed of drug release, and continuously monitoring to generate release efficiency data; The system adjustment parameter refinement submodule accurately adjusts the parameters of the drug release system based on the release efficiency data, optimizes the parameter settings according to the real-time data, adjusts the reaction sensitivity and time window of the release mechanism, and records the specific operations and results of each adjustment to obtain parameter adjustment records; The efficacy improvement monitoring submodule adjusts the records according to the parameters, makes quantitative adjustments to the drug dosage and release frequency, makes feedback adjustments based on the treatment effect, and records and adjusts the key data and results in the process according to the drug response and pathological changes to obtain the efficacy optimization results.

Citation Information

Cited By

  • Anorectal disease auxiliary treatment monitoring system and method based on Lingshen extract

    CN119479984A

  • Device and method for presetting omaya capsule in brain malignant tumor operation cavity for postoperative chemotherapy

    CN119626445A

  • Self-driven micro-robot for liver tumor targeted therapy and real-time monitoring system

    CN119811577A